Selah Genomics Completes MBO

Selah Genomics has completed the management buyout of Lab21 Inc, the US subsidiary of Lab21 Ltd, led by the existing Lab21 Inc management team. Nexus Medical Partners, SCRA Technology Ventures` Stage 2 Affiliate, SC Launch and the Greenville Local Development Corporation supported the buyout.

PRESS RELEASE

Selah Genomics Inc announces the completion of its management buy-out of Lab21
Inc, the US subsidiary of Lab21 Ltd, led by the existing Lab21 Inc management
team.

Nexus Medical Partners, SCRA Technology Ventures` Stage 2 Affiliate, SC Launch
and the Greenville Local Development Corporation supported the buyout.

Nexus Medical Partners Co-Founders Ed Snape and John Rousseau will join Michael
Bolick on the Selah Genomics board. John Rousseau said: “Selah Genomics performs
genetic testing in laboratories regulated by the U.S. Center for Medicare &
Medicaid Services under the Clinical Laboratory Improvement Amendments (CLIA).
Selah is leveraging the latest in molecular and genomic technologies to develop
companion diagnostics, i.e., tests that can tell doctors when a specific patient
has a DNA mutation that can be targeted by a drug. We look forward to working
with the Selah team in this exciting period for the company as we continue to
grow our South Carolina-based portfolio.”

Michael Bolick, CEO of Selah Genomics comments: “Having been President of Lab21
Inc for the last three years, I am genuinely excited by the opportunity to lead
Selah as we expand our molecular diagnostic testing services from our main CLIA
laboratory in downtown Greenville SC and from our first Clinical Genomics
Center, which is physically located within the Greenville Health System`s
Institute for Translational Oncology Research (ITOR). Our team is uniquely
suited to help advance the genomics revolution into research labs and clinical
trials where drugs are being designed and developed to home in on the specific
molecular drivers of disease. We have a number of exciting developments under
way and look forward to a strong 2013.”

Bill Mahoney, CEO of SCRA, said: “Selah is a diagnostics company at the
forefront of bringing comprehensive genomic analysis to the clinic. This change
in the management of patient care through the use of more precise diagnostic
tests is an exciting development. Selah`s proven skill in determining the
genetic profile of patient samples is vital to today`s clinical trials and the
development of companion diagnostics. We are thrilled to see this continued
growth for one of our leading SC Launch and now Stage 2 portfolio companies.”

About Nexus Medical Partners

Nexus Medical Partners is a private equity firm, headquartered in Boston, MA,
specializing in making private equity investments in and providing strategic
assistance to medical technology and selected life science companies.

About SCRA and SCRA Technology Ventures

SCRA Technology Ventures helps innovative companies grow and develop new
technologies, creating jobs and advancing the Knowledge Economy throughout South
Carolina. This SCRA business sector provides support and mentoring through its
flagship SC Launch program to early stage, start-up technology companies. Since
2006, SCRA has deployed over $59 million in funding and infrastructure to
support over 280 high -tech, early-stage enterprises, and has directly invested
over $13 million in South Carolina start-ups, attracting over $200 million in
private investment. SCRA Technology Ventures also supports commercialization and
growth by facilitating the transfer of intellectual property and accelerating
the transition of inventions to the marketplace. Additionally, SCRA Technology
Ventures invests in more established technology companies through its Stage 2
affiliate.

Selah Genomics Inc
Michael Bolick, 864-751-4815
CEO
Michael.bolick@SelahGenomics.com

Related Posts

Leave a Reply

PEHUB Community

Join the 12501 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget